In Brief: Invacare acquisitions
This article was originally published in The Gray Sheet
Executive SummaryInvacare acquisitions: Home medical equipment firm expands presence in U.K. through $5.1 mil. cash purchase of Bencraft Limited, a Birmingham, England-based manufacturer of powered and manual wheelchairs. Bencraft had about $10 mil. in sales for its fiscal year ended March 21. Invacare also recently purchased Patient Solutions, Inc., which has a four-modality infusion pump that gives Invacare "a totally new product line that many of our existing DME [durable medical equipment]/respiratory provider customers will purchase as they diversify into home infusion therapy." PSI's pump can provide intravascular feeding, intermittent antibiotic therapy, patient-controlled analgesia and chemotherapy. Privately held with about $1-2 mil. in annual sales, PSI will continue to operate out of its San Diego headquarters under current management led by President Dave Davis...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.